Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): A prospective, single-arm, feasibility study

The Lancet Oncology

Volumn 14, Issue 9, 2013, Pages 834-842

  Zsiros, József ^a   Brugieres, Laurence ^b   Brock, Penelope ^c   Roebuck, Derek ^c   Maibach, Rudolf ^d   Zimmermann, Arthur ^e   Childs, Margaret ^f   Pariente, Daniele ^g   Laithier, Veronique ^h   Otte, Jean Bernard ⁱ   Branchereau, Sophie ^j   Aronson, Daniel ^a   Rangaswami, Arun ^k   Ronghe, Milind ^l   Casanova, Michela ^m   Sullivan, Michael ⁿ   Morland, Bruce ^o   Czauderna, Piotr ^p   Perilongo, Giorgio ^q  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d IBCSG Coordinating Center   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Nottingham Clinical Trials Unit   (United Kingdom)

^g BICÊTRE HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k STANFORD UNIVERSITY   (United States)

^l ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ UNIVERSITY OF OTAGO   (New Zealand)

^o BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^p MEDICAL UNIVERSITY OF GDANSK   (Poland)

^q UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN;

ADULT; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEPATOBLASTOMA; HIGH RISK POPULATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFANT; INFECTION; INTENTION TO TREAT ANALYSIS; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS RESECTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84880844862     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70272-9     Document Type: Article

References (30)

1. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach-results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000, 18:3819-3828.
2. Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000, 89:1845-1853.
3. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 2004, 40:411-421.
4. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009, 361:1662-1670.
5. Von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997, 33:1243-1249.
6. Fuchs J, Bode U, Von Schweinitz D, et al. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94. Klin Padiatr 1999, 211:305-309. (in German).
7. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002, 95:172-182.
8. Haberle B, Bode U, von Schweinitz D Differentiated treatment protocols for high- and standard-risk hepatoblastoma-an interim report of the German Liver Tumor Study HB99. Klin Padiatr 2003, 215:159-165. (in German).
9. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol 1991, 9:2167-2176.
10. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000, 18:2665-2675.
11. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol 2002, 20:3438-3444.
12. Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 2006, 24:2879-2884.
13. Matsunaga T, Sasaki F, Ohira M, et al. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 2003, 19:142-146.
14. Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 2011, 27:1-8.
15. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010, 28:2584-2590.
16. Citron ML Dose-dense chemotherapy: principles, clinical results and future perspectives. Breast Care (Basel) 2008, 3:251-255.
17. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
18. Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003, 21:2466-2473.
19. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist 2005, 10:138-149.
20. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
21. Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010, 102:1845-1854.
22. Nitschke R, Fagundo R, Berry DH, Falletta JM Weekly administration of cis-dichlorodiammineplatinum(II) in childhood solid tumors: a Southwest Oncology Group study. Cancer Treat Rep 1979, 63:497-499.
23. Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2007, 37:123-132.
24. Roebuck DJ, Olsen O, Pariente D Radiological staging in children with hepatoblastoma. Pediatr Radiol 2006, 36:176-182.
25. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991, 19:295-300.
26. Haas JE, Feusner JH, Finegold MJ Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 2001, 92:3130-3134.
27. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer 2008, 44:545-550.
28. Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era-recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 2005, 41:1031-1036.
29. Otte JB, de Ville de GJ, Reding R Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 2005, 9:557-565.
30. Otte JB Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev 2010, 36:360-371.